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Induced Emesis 
Theresa Fennell, Samantha Spitak, Emily Smith, Teresa Garrett, James B. Lucot 
 Department of Pharmacology and Toxicology, Wright State University, Dayton, OH 
‐ ‐
 Introduction 
Drugs currently used to prevent emesis (nausea and vomiting) target only one or a few 
of the pathways used by emetic stimuli to trigger the reflex. Thus, an anti-emetic drug 
will only be effective against some stimuli. Prior work determined that 8-OH-DPAT 
(DPAT, a 5-HT1A agonist) was a universally effective anti-emetic. Although DPAT 
prevented emesis, it also elicited an extreme anxiety response making it unsuitable for 
therapeutic use. Our laboratory tested a proprietary drug developed from DPAT, ETI-
385, to successfully prevent emesis in musk shrews against chemotherapy, drug and 
motion stimuli. To meet FDA regulations, we are required to test ETI-385 in another 
species before taking the drug into clinical trials. Work at Epiomed Therapeutics used 
ETI-385 to successfully prevent emesis in cats using motion stimuli and found a 
separation between the anti-emetic and anxiety-producing doses.  
 
Objectives 
• Determine the efficacy of ETI-385 in preventing symptoms of emesis against a drug           
stimulus. 
• Determine any adverse side effects 
Methods 
We determined a dose response curve for ETI-385 administered 20 min before 0.66 mg/kg of Xylazine 
administered subcutaneously (SC.) After Xylazine administration they were placed in a Plexiglas 
observation chamber. Once in the chamber, the animals were transported to our testing room for a 30 
minute observation. After observation, the animals were transported to the housing room where they 
were released to their home cages. The animals were released to the common room after their 
behavior was determined to be suitable for interspecies interaction. All procedures approved by IACUC. 
 
Drug 
ETI-385 is a proprietary drug  developed by Epiomed Theraputics. ETI-385 is derived from DPAT, a     
5-HT1A agonist. The drug was prepared once every two weeks and refrigerated until dilution.  
 
Subjects 
6 female domestic cats aged six months were used. They were housed in an AAALAC approved facility 
on a 12hr light/dark cycle with free access to food and water. Before administration of drugs animals 
were housed overnight in cages.  
 
Scoring 
During observation the time of latency to first vomit was recorded. The animals were also scored for 
symptoms of both emesis and anxiety. Each symptom of emesis was assigned a point value. The total  
score values for each animal were combined.  A high symptom score is indicative of nausea whether or 
not emesis occurs. 
 
 Emetic Symptom Point Value 
 Salivation 1 (abundant saliva production) 1 point 
 Salivation 2 (thick, frothy saliva) 2 points Table 1. Emetic 
 Salivation 3 (thick, stringy saliva) 4 points symptoms and their 
 Panting (quick, heavy  breathing) 2 points description.  
 Defecation (no description needed) 8 points 
 Urination (no description needed) 8 points 
 Vomit 1 (no description needed) 16 points 
 
Results 





Figure 1. Percentage of shrews who vomited at each 
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Figure 2. Percentage of shrews who vomited at each 
does of ETI-385 against cisplatin. 
Emetic Response in Cats 
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Figure 3. Average  score after treatment with ETI-385 and 
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Figure 5. Latency to first vomit after treatment with ETI-






• 0.0225mg/kg was unsuccessful in preventing emesis and produced a higher symptom 
score than Xylazine alone, suggesting nausea.  
•  0.045mg/kg was 66.7% effective against vomiting but had an increase in symptom 
score  
•  0.09mg/kg was 83.4% effective against vomiting with a marked decrease in symptom 
score. 
•  At the 0.36 mg/kg dose we achieved 100% efficacy and a complete eradication of 
emetic symptoms. 
•  Unlike DPAT, only the highest dose of ETI-385 produced any defensive behavior. 
